Everest Medicines Announces Publication of Etrasimod’s Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology
HONG KONG, Oct 9, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that the results of its Asian multicenter Phase III ENLIGHT UC study (ES101002) of etrasimod...
